All Posts

Platform Reduces Non-Specific Uptake & Combats Resistance with Payload Diversity; Enables High DAR exatecan ADCs, Dual Payloads, & Degrader Antibody Conjugates PALO ALTO, CA, UNITED STATES, August 13, 2025 -- Baylink Biosciences, a biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, today announced it will present its proprietary linker and payload platforms at the 3rd ADC Linker & Conjugation Summit, taking place August 19–21, 2025, i

Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors supports potential best-in-class profile. Data presented demonstrating Baylink’s innovative ADC linker technology is overcoming major challenges in ADC development. PALO ALTO, Calif., April 25, 2025 -- Baylink Biosciences presented data from its Antibody Drug Conjugate portfolio at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. The data presented for BLB-101, an ant

Preclinical results for lead ADC candidate BLB-101 for Claudin 6/9+ tumors to be presented Data supporting the rationale for Baylink’s innovative ADC linker technology enabling delivery of degraders, dual payload antibody drug conjugates, and high drug to antibody ratio chemotherapy will be presented . PALO ALTO, Calif., April 15, 2025 -- Baylink Biosciences today announced that new preclinical data from its portfolio will be presented at the American Association for Cancer R

Members of Baylink's management team will be participating in the Annual Meeting of American Association of Cancer Research being held...

Members of Baylink Biosciences management team will be participating in the LSX World Congress meeting April 29-30th in London. Darren...